Raised serum transaminase levels in patients with rheumatic fever treated with salicylates.
Of 11 patients with acute rheumatic fever, 9 were treated with a total daily salicylate dosage of 3,6 g or less, 1 patient required a total daily dosage of 5,4 g and another required 9,0 g daily. Six of the 11 patients had elevated serum transaminase levels, and all were asymptomatic. The elevated transaminase levels appear to bear a direct relationship to the serum salicylate level, and a serum salicylate level of 19,2 mg/100 ml appears to be the critical point. In 5 out of the 6 patients with elevated transaminases, the serum salicylate level exceeded 19,2 mg/100 ml, while in the 5 patients with normal transaminases the serum salicylate level did not exceed 19,2 mg/100 ml. Also, in 10 of the 11 patients eosinophilia was noted, but this decreased despite continued or increased salicylate administration. A narrow margin thus appears to exist between therapeutic serum salicylate levels and hepatotoxic levels, and serial serum transaminase estimations are advocated in patients on long-term salicylate therapy.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D004802:Eosinophilia / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D012213:Rheumatic Fever / Q000097:blood / Q000201:enzymology*; D012459:Salicylates / Q000009:adverse effects* / Q000097:blood
D012459:Salicylates; D001219:Aspartate Aminotransferases